Search Results

Three-Year DURABILITY II Results Support Single-Stent Strategy for Symptomatic SFA/PPA Disease

February 25, 2015—Krishna J. Rocha-Singh, MD, et al conducted an evaluation of longer-term safety and efficacy of a single self-expanding stent up to 20 cm in length in patients with atherosclerotic disease of the superficial femoral artery (SFA) and proximal popliteal artery (PPA) and concluded that this treatment provides reasonable long-term outcomes when intervention is required for symptomatic SFA and PPA disease. The study’s findings are available online ahead of print in Catheterization and Cardiovascular Interventions.

XCELL Data Support Infrapopliteal Use of Abbott's Xpert Stent in Patients With CLI

July 24, 2012—Krishna J. Rocha-Singh, MD, et al published findings from the XCELL trial, an evaluation of the safety and effectiveness of the Xpert self-expanding nitinol stent (Abbott Vascular, Santa Clara, CA) in Rutherford class 4 to 6 patients with infrapopliteal lesions that are 4 to 15 cm in length. The investigators noted in the background of the study that percutaneous transluminal angioplasty with stent deployment in infrapopliteal arteries is an accepted but unproven therapy for patients with critical limb ischemia (CLI). The study is available online ahead of print in Catheterization and Cardiovascular Interventions.

VIVA I: Xcell Results Presented for Abbott Vascular's Xpert Stent to Treat CLI

October 22, 2009—Six-month clinical results from the VIVA I: Xcell trial were presented for the first time by Krishna J. Rocha-Singh, MD, in the late-breaking trials session at the VIVA: Vascular Interventional Advances meeting in Las Vegas, Nevada.

VIVA's Paclitaxel Analysis Finds Increased Mortality Risk, But No Dose Association; Lead Author Encourages Close Read

May 27, 2020—Earlier this month, VIVA Physicians announced the publication of an analysis of mortality and paclitaxel-coated devices by Krishna Rocha-Singh, MD, et al, which is available online ahead of print in Circulation.

VIVA 2009 Late-Breaking Trials Highlight Advances in Interventional Treatments of Peripheral Vascular Disease

November 9, 2009—VIVA Physicians, Inc. (San Jose, CA) announced that the latest data from seven studies focused on the treatment of peripheral arterial disease were presented in the late-breaking trials session of the VIVA 2009: Vascular Interventional Advances annual meeting held on October 19 through 23 in Las Vegas, Nevada.